However, when GW9662, a PPAR-γ antagonist, was co-administered with hesperidin, it attenuated the beneficial effects of hesperidin, supporting the notion that the protective impact of hesperidin against gastric ulcers is indeed mediated through PPAR-γ activation. The gene discussed is PPARG; the disease is gastric ulcer.